Navigation Links
Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)
Date:10/20/2008

CHAPEL HILL, N.C., Oct. 20 /PRNewswire/ -- With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, pharmaceutical, biotechnology and medical device industry executives are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes. In the recently published report by benchmarking firm, Best Practices, LLC, reviewing the CME support functions, benchmark respondents found significant opportunity for maximizing resources through centralization and innovative use of E-CME. Data from this study, "Educating the Market: Creating Value through Support of Continuing Medical Education," identified several key practices and metrics that can enable organizations to identify performance gaps and areas for improvement to better manage their CME support functions.

To view the study abstract or complimentary summary of the full report "Educating the Market: Creating Value through Support of Continuing Medical Education," click on the following link http://www3.best-in-class.com/rr971.htm .

In a benchmarking study that included such influential companies as AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson & Johnson, Merck, Pfizer, Roche, Sanofi-Aventis and Wyeth, many key questions were covered, including:

-- What is the current landscape of continuing medical education (CME) in

North America and Europe?

-- What structural forms are used to deploy CME, optimize budgets & best

deliver content?

-- How rapidly is E-CME advancing?

-- What CME delivery channels are preferred?

-- What are the current trends and future directions of CME?

Among the key topics gathered in this report are:

-- Geographic delivery of CME

-- Structural management of CME

-- CME investment budgets for North America

-- CME investment budgets for Europe

-- CME investment staffing for North America

-- CME investment staffing for Europe

-- Mix of planned versus spontaneous CME investment

-- Functional responsibility for CME

-- Mix of CME delivery in North America (company directed versus 3rd

party, etc.)

-- Mix of CME delivery in Europe

-- Background & experience of CME employees

-- Tenure of CME employees

-- Mix of CME delivery modes for North America

-- Mix of CME delivery modes for Europe

-- Use of E-CME in North America & Europe

-- Effectiveness ratings for CME delivery activities in North America

-- Effectiveness ratings for CME delivery activities in Europe

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr971.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
2. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
3. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
4. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
5. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
6. Best Practice Database Supports Bio-Pharma Product Launch
7. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
8. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
9. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
10. Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
11. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):